Enzymes, Signaling Proteins, Extracellular Ligands, Signaling Reagents, Antibodies
| Shopping Cart EN/中文
Announcement : SignalChem has changed its corporate name from “SignalChem Pharmaceutical Inc.” to “SignalChem Biotech Inc.” effective March 20th 2019.
 

GROWTH FACTORS - OPG (O878-40N)

Product Name Catalog Number Pack Size Price(USD)  
OPG O878-40N-10 10 ug $204 Contact Us
OPG O878-40N-50 50 ug $325 Contact Us
OPG O878-40N-BULK BULK Contact Us  


Description: Recombinant human OPG was expressed in E. coli cells and purified by proprietary chromatographic techniques.


Purity : Sample Purity Data. For specific information on a given lot, see related technical data sheet.



Storage, Stability and Shipping : Stored at desiccated below -20oC. It is stable at 4oC between 2-7 days. For long term storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications : Cell Assay

Endotoxin Level : Less than 0.1 ng/ug (IEU/ug) of OPG.

Molecular Weight : ~21 kDa

Gene Aliases : TNFRSF11B; TR1; OCIF; MGC29565

Scientific Background : OPG is an 11b member of tumor necrosis factor receptor superfamily which is an osteoblast-secreted decoy receptor that functions as a negative regulator of bone resorption. OPG can act as a soluble factor in the regulation of bone mass and it may be useful in the treatment of osteoporosis associated with increased osteoclast activity (1). osteoprotegerin ( OPG) is an independent risk factor for the progression of atherosclerosis and onset of cardiovascular disease. OPG also play a critical role in the development of osteolytic bone disease in multiple myeloma and that targeting this system may have therapeutic potential (2).

References :
1. Simonet, W. S. et.al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.

2. Croucher, P. I. et.al: Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98: 3534-3540, 2001.

Product Sheets

Research Areas
Cardiovascular Disease, Inflammation,

Related Products

  Terms of Service | Privacy Policy  
  @ 2018 SignalChem.All rights reserved